Similar articles

• Cancer: some reasons to be hopeful.

  [No authors listed] [No authors listed] Lancet. 2007 Feb 17;369(9561):531. doi: 10.1016/S0140-6736(07)60243-8. Lancet. 2007. PMID: 17307079 No abstract available.
• Switching to aromatase inhibitors in early breast cancer.

  Boccardo F, Rubagotti A. Boccardo F, et al. Lancet. 2007 Feb 17;369(9561):533-5. doi: 10.1016/S0140-6736(07)60201-3. Lancet. 2007. PMID: 17307082 No abstract available.
• Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

  Jahanzeb M. Jahanzeb M. Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
• Exemestane for primary prevention of breast cancer in postmenopausal women.

  Zhang Y, Simondsen K, Kolesar JM. Zhang Y, et al. Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585. Am J Health Syst Pharm. 2012. PMID: 22855103
• [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].

  van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW. van Nes JG, et al. Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9. Ned Tijdschr Geneeskd. 2006. PMID: 17319217 Review. Dutch.